Brilliant event! How amazing to catch up with colleagues in person again. Blown away by all the exciting research our department has to offer! Big thanks to Department of Cardiovascular Sciences - KU Leuven!

Early in the pandemic, our center switched to a weight- and severity adjusted intensified thromboprophylactic protocol in #COVID19. In RPTH we discuss the promising results and the randomized data available to date Peter Verhamme UZ Leuven Center for Molecular and Vascular Biology Department of Cardiovascular Sciences - KU Leuven

This well-performed RCT compares therapeutically dosed (intervention) with weight and severity adjusted (control) #thromboprophylaxis in #COVID19; showing good prognosis in both groups #VTE #thrombosis #DIC #majorbleeding #death

Belgische arts Laurens Liesenborghs onderzoekt apenpokken in Congo: "Variant in Westen wellicht milder" vrt.be/vrtnws/nl/2022…

After implementing a weight- & illness severity-adjusted thromboprophylaxis regimen, this single-center eliminated symptomatic #VTE, ⬇️ incidental VTE, & lowered risk of bleeding compared to standard prophylaxis. onlinelibrary.wiley.com/doi/10.1002/rt… Matthias M Engelen Christophe Vandenbriele Kim Martinod

CMVB tomorrow at #ISTH2022 meeting !! Presentations from Matthias M Engelen on COVID and the DAWn_Antico study & Kim Martinod on recommendations for NETs measurements in SSC session. Also posters from Valérie Spalart and again Matthias M Engelen

In this multicenter RCT, upstream + downstream modulation of thromboinflammation in hospitalized mod/severe COVID19 patients using cocktail of high-dose aprotinin + LMWH +/- anakinra was safe but did not improve clinical or biochemical outcomes vs SOC. #ISTH2022 Matthias M Engelen

Dr. Matthias M Engelen presenting data showing no additional effect of targeting the kallikrein pathway on improving outcomes in #COVID19 #ISTH2022

Modulation of Host Thromboinflammatory Response in Hospitalized Patients with COVID-19: The DAWn-Antico Study. An absolute highlight of ISTH 2022! ⁦Matthias M Engelen⁩ isthcongressdaily.org/Articles/ArtMI…

Watch Matthias M Engelen MD present #ISTH2022 news on DAWn-Antico Study on modulation of host thromboinflammatory response in hospitalized COVID patients. Spend 7 info-packed minutes: mededonthego.com/Video/program/…

Very honored with this RPTH Editor's Award! Many thanks to all colleagues and participating centers for their efforts in challenging times! Thomas Vanassche Peter Verhamme UZ Leuven GZA Ziekenhuizen ZOL

Delighted to discuss these important steps for patients with acquired hemophilia A (AHA) together with all colleagues here at #ISTH2023 🇨🇦! Details of our talk on emicizumab in AHA now available online 👉🏻 buff.ly/3Pdt2fV

Such an honour to be awarded with a RPTH Early Career Editor’s Awards at #ISTH2023 by the amazing Mary Cushman 🫀🧠🩸, together with mentors Thomas Vanassche and Peter Verhamme for our paper on modulation of thromboinflammation in #COVID19 👉🏻 rpthjournal.org/article/S2475-…

Make sure to keep an eye open for the PRIORITY results in the coming years! After reading the protocol paper of this multicenter prospective RCT in patients along the HFpEF continuum (stage A-C), you will understand what all the buzz is about! 🐝 🫀 👏🏻

🫀 Predictors of and outcome in arrhytmic mitral valve prolapse 👥 169 patients with MVP who underwent CMR 👉 LGE and MAD as only predictors of AMVP 💡 Low event rates ↔️ ICD implantation reasonable in 69.7% patients according EHRA consensus #CMR #Cardiology AmericanHeartJ

📢Urinary chemokines CXCL9&10 integrated with clinical parameters for noninvasive monitoring of rejection could significantly reduce the number of biopsies🔬. This study paves the way🛣️ for implementation in clinical practice 🏥

📰👀 Exercise Pulmonary Hypertension by the mPAP/CO slope in Primary Mitral Regurgitation. Read our last paper in European Society of Cardiology Journals: academic.oup.com/ehjcimaging/ar… 🧵✅ 🇧🇪Philippe B. Bertrand Jan Verwerft Lieven Herbots Sarah Hoedemakers Youri Bekhuis Maarten Falter Ruta Jasaityte Pieter Vandervoort

👇🏼 Very proud of these novel data, potential clinical impact +++ Great collaboration between ZOL & Jessa Ziekenhuis, Fac. Geneeskunde & Levenswetenschappen UHasselt 🇧🇪 Importance of exercise PHT by mPAP/CO slope in risk-stratification of primary MR. Jan Verwerft Sebastiaan Dhont

Everything you need to know about atrial myopathy, a comprehensive review by the amazing michieltubeeckx

FXI inhibitors promise to prevent thrombosis while maintaining hemostasis. In this recent review, the authors provided insights into FXI inhibitors and future perspectives. Peter Verhamme Matthias M Engelen Elsevier Hematology #ThrJournal Read more here: sciencedirect.com/science/articl…